Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.8380
-0.0410 (-4.66%)
Aug 13, 2025, 4:00 PM - Market closed
Paramount Global Revenue
Nexalin Technology had revenue of $70.59K in the quarter ending June 30, 2025, with 163.00% growth. This brings the company's revenue in the last twelve months to $174.81K, up 16.42% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.
Revenue (ttm)
$174.81K
Revenue Growth
+16.42%
P/S Ratio
61.10
Revenue / Employee
$29,136
Employees
6
Market Cap
14.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NXL News
- 12 days ago - Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives - GlobeNewsWire
- 2 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3 - GlobeNewsWire
- 3 months ago - Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data - GlobeNewsWire
- 3 months ago - Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback - GlobeNewsWire
- 3 months ago - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewsWire
- 4 months ago - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - GlobeNewsWire